Cardiac resynchronization therapy in mildly symptomatic heart failure: the earlier the better

References

• Liu P, Arnold JMO, Belenki I et al. The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure. Can. J. Cardiol.19, 347–356 (2003).
   PubMedGoogle Scholar
• Arnold JMO, Liu P, Demers C et al. Canadian Cardiovascular Society consensus recommendations on heart failure 2006: diagnosis and management. Can. J. Cardiol.22, 23–45 (2006).
   PubMed Web of Science ®Google Scholar
• Dickstein K, Vardas PE, Auricchio A et al. 2010 focused update of ESC guidelines on device therapy in heart failure. An update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur. J. Heart Fail.12, 1143–1153 (2010).
   PubMedGoogle Scholar
• Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J. Am. Coll. Cardiol.52(23), 1834–1843 (2008).
   PubMed Web of Science ®Google Scholar
• Moss AJ, Hall WJ, Cannom DS et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N. Engl. J. Med.361(14), 1329–1338 (2009).
   PubMed Web of Science ®Google Scholar
• Tang AS, Wells GA, Talajic M et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N. Engl. J. Med.363(25), 2385–2395 (2010).
   PubMed Web of Science ®Google Scholar
• Dickstein K, Vardas PE, Auricchio A et al. 2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Europace12(11), 1526–1536 (2010).
   PubMed Web of Science ®Google Scholar
• Hesse B, Diaz LA, Snader CE, Blackstone EH, Lauer MS. Complete bundle branch block as an independent predictor of all-cause mortality: report of 7,073 patients referred for nuclear exercise testing. Am. J. Med.110(4), 253–259 (2001).
   PubMed Web of Science ®Google Scholar
• Curry CW, Nelson GS, Wyman BT et al. Mechanical dyssynchrony in dilated cardiomyopathy with intraventricular conduction delay as depicted by 3D tagged magnetic resonance imaging. Circulation101(1), E2 (2000).
   PubMed Web of Science ®Google Scholar
• Cazeau S, Ritter P, Bakdach S et al. Four chamber pacing in dilated cardiomyopathy. Pacing Clin. Electrophysiol.17(11 Pt 2), 1974–1979 (1994).
   PubMed Web of Science ®Google Scholar
• Cazeau S, Ritter P, Lazarus A et al. Multisite pacing for end-stage heart failure: early experience. Pacing Clin. Electrophysiol.19(11 Pt 2), 1748–1757 (1996).
   PubMedGoogle Scholar
• Leclercq C, Cazeau S, Le Breton H et al. Acute hemodynamic effects of biventricular DDD pacing in patients with end-stage heart failure. J. Am. Coll. Cardiol.32(7), 1825–1831 (1998).
   PubMed Web of Science ®Google Scholar
• Auricchio A, Stellbrink C, Block M et al. Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. The Pacing Therapies for Congestive Heart Failure Study Group. The Guidant Congestive Heart Failure Research Group. Circulation99(23), 2993–3001 (1999).
   PubMed Web of Science ®Google Scholar
• Nelson GS, Curry CW, Wyman BT et al. Predictors of systolic augmentation from left ventricular preexcitation in patients with dilated cardiomyopathy and intraventricular conduction delay. Circulation101(23), 2703–2709 (2000).
   PubMed Web of Science ®Google Scholar
• Nelson GS, Berger RD, Fetics BJ et al. Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. Circulation102(25), 3053–3059 (2000).
   PubMed Web of Science ®Google Scholar
• Cazeau S, Leclercq C, Lavergne T et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N. Engl. J. Med.344(12), 873–880 (2001).
   PubMed Web of Science ®Google Scholar
• Auricchio A, Stellbrink C, Sack S et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J. Am. Coll. Cardiol.39(12), 2026–2033 (2002).
   PubMed Web of Science ®Google Scholar
• Abraham WT, Fisher WG, Smith AL et al. Cardiac resynchronization in chronic heart failure. N. Engl. J. Med.346(24), 1845–1853 (2002).
   PubMed Web of Science ®Google Scholar
• Auricchio A, Stellbrink C, Butter C et al. Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. J. Am. Coll. Cardiol.42(12), 2109–2116 (2003).
   PubMed Web of Science ®Google Scholar
• Young JB, Abraham WT, Smith AL et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA289(20), 2685–2694 (2003).
   PubMed Web of Science ®Google Scholar
• Higgins SL, Hummel JD, Niazi IK et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J. Am. Coll. Cardiol.42(8), 1454–1459 (2003).
   PubMed Web of Science ®Google Scholar
• St John Sutton MG, Plappert T, Abraham WT et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation107(15), 1985–1990 (2003).
   PubMed Web of Science ®Google Scholar
• Bristow MR, Saxon LA, Boehmer J et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N. Engl. J. Med.350(21), 2140–2150 (2004).
   PubMed Web of Science ®Google Scholar
• Cleland JG, Daubert JC, Erdmann E et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med.352(15), 1539–1549 (2005).
   PubMed Web of Science ®Google Scholar
• The CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet353(9146), 9–13 (1999).
   PubMed Web of Science ®Google Scholar
• Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet362(9377), 7–13 (2003).
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med.341(10), 709–717 (1999).
   PubMed Web of Science ®Google Scholar
• Abraham WT, Young JB, Leon AR et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation110(18), 2864–2868 (2004).
   PubMed Web of Science ®Google Scholar
• Daubert C, Gold MR, Abraham WT et al. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction. J. Am. Coll. Cardiol.54, 1837–1846 (2009).
   PubMed Web of Science ®Google Scholar
• St John Sutton M, Ghio S, Plappert T et al. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation120(19), 1858–1865 (2009).
   PubMed Web of Science ®Google Scholar
• Poole JE, Gleva MJ, Mela T et al. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation122(16), 1553–1561 (2010).
   PubMed Web of Science ®Google Scholar
• Solomon SD, Foster E, Bourgoun M et al. Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: multicenter automatic defibrillator implantation trial: cardiac resynchronization therapy. Circulation122(10), 985–992 (2010).
   PubMed Web of Science ®Google Scholar
• Lindenfeld J, Feldman AM, Saxon L et al. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation115(2), 204–212 (2007).
   PubMed Web of Science ®Google Scholar
• Herweg B, Ilercil A, Cutro R et al. Cardiac resynchronization therapy in patients with end-stage inotrope-dependent class IV heart failure. Am. J. Cardiol.100(1), 525–528 (2007).
   Google Scholar
• Cowburn PJ, Patel H, Jolliffe RE, Wald RW, Parker JD. Cardiac resynchronization therapy: an option for inotrope-supported patients with end-stage heart failure? Eur. J. Heart Fail.7(2), 215–217 (2005).
   PubMedGoogle Scholar
• Bhattacharya S, Abebe K, Simon M, Saba S, Adelstein E. Role of cardiac resynchronization in end-stage heart failure patients requiring inotrope therapy. J. Cardiac Fail.16(12), 931–937 (2010).
   PubMedGoogle Scholar
• Chung ES, Leon AR, Tavazzi L et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation117(20), 2608–2616 (2008).
   PubMed Web of Science ®Google Scholar
• Wilton SB, Leung AA, Ghali WA et al. Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm8, 1088–1094 (2011).
   PubMed Web of Science ®Google Scholar
• McAlister FA, Ezekowitz J, Hooton N et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA297(22), 2512–2514 (2007).
   Google Scholar
• Moss AJ, Zareba W, Hall J et al. Prophylactic implantation of a debribrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med.346, 877–883 (2002).
   PubMed Web of Science ®Google Scholar
• Bardy GH, Lee K, Mark DB et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med.352, 225–237 (2005).
   PubMed Web of Science ®Google Scholar
• Bristow M, Saxon L, DeMarco T et al. What does an ICD add to CRT in advanced heart failure? An analysis of major clinical endpoints in the CRT vs CRT-D groups in the COMPANION study. Circulation112, II–673 (2005).
   Google Scholar
• Cleland J, Freemantle N, Ghio S et al. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline vardiables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. J. Am. Coll. Cardiol.52(6), 438–45 (2008).
   PubMed Web of Science ®Google Scholar
• McAlister FA, Tu JV, Newman A et al. How many patients with heart failure are eligible for cardiac resynchronization? Insights from two prospective cohorts. Eur. Heart J.27(3), 323–329 (2006).
   PubMedGoogle Scholar
• Yu CM, Chan JY, Zhang Q et al. Biventricular pacing in patients with bradycardia and normal ejection fraction. N. Engl. J. Med.361(22), 2123–2134 (2009).
   PubMed Web of Science ®Google Scholar
• Bertini M, Delgado V, Bax JJ, van de Veire NR. Why, how and when do we need to optimize the setting of cardiac resynchronization therapy? Europace11, v46–v57 (2009).
   PubMed Web of Science ®Google Scholar
• Ellenbogen KA, Gold MR, Meyer TE et al. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial. Circulation122, 2660–2668 (2010).
   PubMed Web of Science ®Google Scholar
• Mullens W, Grimm RA, Verga T et al. Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. J. Am. Coll. Cardiol.53, 765–73 (2009).
   PubMed Web of Science ®Google Scholar
• Yu CM, Wing-Hong Fung J, Zhang Q, Sanderson JE. Understanding nonresponders of cardiac resynchronization therapy – current and future perspectives. J. Cardiovasc. Electrophysiol.16(10), 1117–1124 (2005).
   PubMedGoogle Scholar
• Exner DV. Is it time to expand the use of cardiac resynchronization therapy to patients with mildly symptomatic heart failure? J. Am. Coll. Cardiol.54(20), 1847–1849 (2009).
   PubMedGoogle Scholar